Chinese pharmaceutical enterprises focus on the "Indian model"

Nearly 200 representatives from China's pharmaceutical industry, University and research attended the 60 Year Summit Forum on Chinese antibiotics held in Chengdu today The reporter learned from the meeting that Chinese pharmaceutical enterprises are "optimistic" about the development path of Indian pharmaceutical manufacturing industry and strive to move from made in China to create in China as soon as possible In the rise and future of China's antibiotic industry, Yue Jin, a representative of Shiyao group, mentioned that a recent report by Puhua Yongdao Zui showed that by 2020, the size of the pharmaceutical market in Brazil, Russia, India, China (collectively referred to as BRIC), Indonesia, Mexico and Turkey will account for one fifth of the global pharmaceutical market At present, India's pharmaceutical manufacturing industry accounts for 8% of the world's pharmaceutical output, and 25% of the finished drugs are exported to the international market China is already a big exporter of antibiotic raw materials such as penicillin How to move from a big antibiotic country to a strong one, the key is to develop new drugs and play the "China created" brand Chen Mao, general manager of Guangzhou Baiyunshan Pharmaceutical Co., Ltd., thinks that the hardware level of China's pharmaceutical industry has reached the international requirements, and the current difficulties lie in the environment From imitation to creation, this is the way that Chinese medicine industry is practicing After the financial crisis, the main reason why the Chinese medical and pharmaceutical industry did not enter the foreign market was that it was not familiar with the foreign policy environment at that time and could not enter the foreign market rashly China's pharmaceutical industry has developed rapidly this year, and it is only a matter of time before it goes international